tirzepatide
5 articles tagged with ‘tirzepatide’
Tirzepatide vs Retatrutide: Evidence, Mechanisms, Safety
This reference distinguishes randomized trial evidence from extrapolation for tirzepatide and retatrutide, clarifying mechanisms and safety. It highlights the absence of direct head-to-head trials and the limits of current data.
GLP-1 Receptor Agonist Peptides: A 2026 Research Landscape
An overview of the GLP-1 receptor agonist research landscape in 2026, covering semaglutide, tirzepatide, retatrutide, and emerging dual- and triple-agonist peptides.
Semaglutide vs Tirzepatide: A Research Comparison
Comparing the mechanisms, receptor pharmacology, and preclinical profiles of semaglutide and tirzepatide — two of the most studied GLP-1 receptor agonist peptides in modern research.
U.S. Telehealth Platforms for GLP-1 Peptides and Research Suppliers
Licensed U.S. telehealth platforms provide prescriptions for GLP-1 medications such as semaglutide and tirzepatide, along with NAD+ injections and other peptide therapies, shipped directly to patients. These services include online consultations and operate in most states. Research peptide suppliers offer compounds like GLP-1 agonists with high purity levels from independent testing.
Is Tirzepatide a Peptide? Resolving Common Terminology Confusion
Many researchers ask if tirzepatide qualifies as a peptide, along with related queries like tirzepatide versus peptides or if it contains peptides. Tirzepatide is indeed a 39-amino-acid synthetic peptide featuring fatty acid conjugation, which extends its half-life to about 5 days. This guide clarifies the biochemical definition, key differences from native peptides like BPC-157, and why the confusion persists in research contexts.